Abstract
Carboplatin clearance depends on the glomerular filtration rate (GFR), and Calvert's formula is frequently used to achieve a target area under the time vs concentration curve (mg ml(-1) min). Creatinine clearance is a substitute for GFR when creatinine values are determined by the Jaffé method, which is being replaced by the enzymatic method. When the enzymatic method is used, the corresponding creatinine clearance theoretically exceeds GFR, and the use of creatinine clearance as GFR in Calvert's formula results, accordingly, in overdosing of carboplatin. In this study, we have established a model for adjusting the creatinine clearance to offset this bias based on a relationship between creatinine values measured by the Jaffé method and by the enzymatic method: adjusted creatinine clearance (ml min(-1)) = creatinine clearance (ml min(-1)) x [serum creatinine (mg dl(-1))]/[serum creatinine (mg dl(-1)) + 0.2]. Subsequently, we validated this model using the data from 35 lung cancer patients. Estimated clearances of carboplatin with the original equation [creatinine clearance + 25] were systematically higher than observed clearances [mean prediction error (MPE) +/- standard error (s.e.) = 26 +/- 5%]. This positive bias was corrected by the adjustment (MPE +/- s.e. = 5 +/- 4%). When the enzymatic method is used, the adjusted creatinine clearance should be used in Calvert's formula.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ando, Y., Minami, H., Saka, H. et al. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer 76, 1067–1071 (1997). https://doi.org/10.1038/bjc.1997.509
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.509
This article is cited by
-
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022
Clinical and Experimental Nephrology (2024)
-
Pediatric onco-nephrology: time to spread the word
Pediatric Nephrology (2021)
-
Guidelines for treatment of renal injury during cancer chemotherapy 2016
Clinical and Experimental Nephrology (2018)
-
Association of serum uric acid with subsequent arterial stiffness and renal function in normotensive subjects
Hypertension Research (2017)
-
Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
Cancer Chemotherapy and Pharmacology (2016)